Tag: combination

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEEDHAM, Mass, Aug. 11, 2025 (GLOBE NEWSWIRE) -- McKinley Acquisition Corporation (the “Company”), announced the pricing of its initial public offering of 15,000,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-tenth (1/10) of one Class A ordinary share upon consummation of the Company’s initial business combination. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the symbol “MKLYU” beginning on August 12, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights will be traded on Nasdaq under the symbols “MKLY” and “MKLYR,” respectively.

Posts Positive Organic Growth and Adjusted EBITDA^‎1 of 23.5% of Revenue

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.